N/A N=69 Using the Canary Breathing System for Panic Disorder Patients
Panic Disorder
Primary: Percent of Subjects Achieving a 40% Decrease in Overall PDSS Score (Clinically Significant Response) — 33 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=29 Trial of Carvedilol in Alzheimer's Disease
Alzheimer's Disease
Primary: Hopkins Verbal Learning Test (HVLT) Scores at Baseline, 3, and 6 Months — 13; 12; 12; 13 Scores on a scale — p=0.565
Phase 2 N=13 Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease
Pompe Disease
Primary: Number of Participants With Adverse Events. — 5; 5 Participants
Phase 2 N=247 Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS) — 11.8; 5.8; 3.6; 3.9 months — p=0.3631
Phase 3 N=126 ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Dyskinesia · Levodopa Induced Dyskinesia (LID) · Parkinson's Disease
Primary: Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 12 — -8.0; -15.9 units on a scale — p=0.0009
N/A N=129 Attachment Based Family Therapy for Suicidal Adolescents
Suicide · Depression · Family Relationships
Primary: Change in the Intensity of Suicidal Ideation Between Intake and End of Treatment — -27.42; -31.55 units on a scale
Phase 3 N=190 Vitamin D Supplementation in HIV Youth
HIV Infections
Primary: Changes in Serum 25(OH)D3 Levels — 11; 22; 7.5; 25 ng/mL
N/A N=35 Non-dispensing Fitting Study Comparing the Clinical Performance Hydrogel Sphere Design Contact Lenses.
Myopia
Primary: Centration - Pair One — 35; 35; 0; 0 number of eyes
Phase 4 N=8 rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Development of CVAD Line Thrombosis — 0 thromboses
Phase 2 N=70 Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
Malaria · Severe Malaria
Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05
Phase 1 N=15 Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Maximum Tolerated Dose — 0.24 mg/kg
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
N/A N=20 Assessment of Left Ventricular Torsion by Echocardiography Study
Hypertrophic Cardiomyopathy
Primary: Accuracy of Doppler Tissue Imaging — 0.57 degrees
Phase 4 N=32 Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake — 0.28; 0.28 umol/min/kg — p=0.9984
Phase 2 N=22 Alzheimer's Disease Acitretin Medication
Alzheimer Disease
Primary: Difference in Cerebrospinal Fluid (CSF) Soluble Alpha-clevaed Amyloid Precursor Protein (APPsα) Concentration at Visit 3 Compared to Baseline — 1.251; 0.8741 fold change…